Sunday, 20 September 2026

iberempresa

IBEX 3519.513,80 -1,60%EuroStoxx 506236,20 -1,37%S&P 5007650,50 +0,17%€/$1,1490 +0,09%Brent99,29 -0,64%Bitcoin70.594 -0,24%
Breaking

The Rise of Stem Cell Therapies Poses Regulatory Risks

Stem cell therapies are on the rise in the US, but their efficacy and safety are questioned. Clinics offer unapproved treatments that may be dangerous.

Álvaro Sáez Ferrer
Álvaro Sáez Ferrer
· 2 min read

Stem cell therapies are gaining popularity, but their efficacy and safety are questioned. Clinics in the US offer unapproved treatments that may be dangerous.

Stem cell therapies are emerging as a growing sector in the United States, where clinics offer unapproved treatments that promise to regenerate tissues and extend life. However, many of these practices lack scientific evidence and are subject to little regulatory oversight, according to expansion.com.

For example, Dr. Heidi Regenass from the Chara Health clinic in Los Angeles describes how stem cells can heal tissues and reduce inflammation. However, she fails to mention that her treatment, which costs $18,450, is not scientifically proven and its sale is illegal under US federal law.

The stem cell market has grown, attracting both patients with chronic illnesses and those seeking longevity treatments. However, the proliferation of pseudoscientific claims and fraudulent products poses a serious public health issue, warns Sean Morrison, former president of the International Society for Stem Cell Research.

The situation is concerning, especially with the stance of the new US Secretary of Health, Robert F. Kennedy Jr, who has expressed his intention to challenge the FDA's regulation of alternative therapies. This trend could intensify the sale of unapproved treatments, putting patients' health at risk.

A recent investigation reveals that many clinics ignore FDA warnings and continue to operate with superficial compliance with regulations, using misleading marketing to attract new patients. The lack of effective regulation allows them to continue offering treatments without proven benefits.

Álvaro Sáez Ferrer

Written by

Álvaro Sáez Ferrer

Redactor

Economista por ICADE y una de las pocas personas que disfruta leyendo la ley de presupuestos. Cafetero, padre a tiempo completo y azote de la letra pequeña; en Iber Empresa escribe de economía y fiscalidad.